Year: 2023
Language: English
This fact sheet contains commonly asked questions and more information on standard half-life (SHL) and extended half-life (EHL) clotting factor replacement therapies.
Learn more about different treatment options for hemophilia with the World Federation of Hemophilia Shared Decision Making tool!
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.
This information sheet is designed to help understand the similarities, differences, and current state of knowledge for the existing genetic
The World Federation of Hemophilia (WFH) hosted an educational webinar titled “Progress toward a cure for hemophilia: gene editing explained”
The World Federation of Hemophilia invited representatives from its national member organizations, national governments, healthcare providers, industry partners, and other
A summary of discussions held at the Thirteenth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which
A summary of discussions held at the Twelfth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which
This video gives a quick introduction to ultra-long half-life (UHL) clotting factor replacement therapy. Learn more about different treatment options
